These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20664588)

  • 1. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
    Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Br J Cancer; 2010 Aug; 103(5):629-41. PubMed ID: 20664588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.
    Coscia M; Quaglino E; Iezzi M; Curcio C; Pantaleoni F; Riganti C; Holen I; Mönkkönen H; Boccadoro M; Forni G; Musiani P; Bosia A; Cavallo F; Massaia M
    J Cell Mol Med; 2010 Dec; 14(12):2803-15. PubMed ID: 19818098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
    Comito G; Pons Segura C; Taddei ML; Lanciotti M; Serni S; Morandi A; Chiarugi P; Giannoni E
    Oncotarget; 2017 Jan; 8(1):118-132. PubMed ID: 27223431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of zoledronic acid on the function and differentiation of myeloid cells.
    Wolf AM; Rumpold H; Tilg H; Gastl G; Gunsilius E; Wolf D
    Haematologica; 2006 Sep; 91(9):1165-71. PubMed ID: 16956814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
    Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
    Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.
    Rietkötter E; Menck K; Bleckmann A; Farhat K; Schaffrinski M; Schulz M; Hanisch UK; Binder C; Pukrop T
    Oncotarget; 2013 Sep; 4(9):1449-60. PubMed ID: 24036536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
    Tsagozis P; Eriksson F; Pisa P
    Cancer Immunol Immunother; 2008 Oct; 57(10):1451-9. PubMed ID: 18297280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct antitumour activity of zoledronic acid: preclinical and clinical data.
    Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C
    Clin Transl Oncol; 2011 Mar; 13(3):148-55. PubMed ID: 21421459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
    Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
    Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
    Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
    Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro.
    Huang X; Huang S; Guo F; Xu F; Cheng P; Ye Y; Dong Y; Xiang W; Chen A
    Mol Med Rep; 2016 Jan; 13(1):613-22. PubMed ID: 26648136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour macrophages as potential targets of bisphosphonates.
    Rogers TL; Holen I
    J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
    Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
    Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
    Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
    Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of macrophage viability, differentiation, and function by bisphosphonates.
    Patntirapong S; Poolgesorn M
    Oral Dis; 2018 Oct; 24(7):1294-1302. PubMed ID: 29869362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.
    Biray Avci C; Kurt CC; Tepedelen BE; Ozalp O; Goker B; Mutlu Z; Dodurga Y; Elmas L; Gunduz C
    Tumour Biol; 2016 May; 37(5):6673-9. PubMed ID: 26646564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
    Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
    Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid.
    Hiroshima Y; Maawy A; Hassanein MK; Menen R; Momiyama M; Murakami T; Miwa S; Yamamoto M; Uehara F; Yano S; Mori R; Matsuyama R; Chishima T; Tanaka K; Ichikawa Y; Bouvet M; Endo I; Hoffman RM
    PLoS One; 2014; 9(8):e103382. PubMed ID: 25116261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
    Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
    BMC Cancer; 2010 Aug; 10():464. PubMed ID: 20804550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.